AUTHORS
Alessandra Vatteroni, MD, Etienne Lengline2, Raphael Itzykson, MD, PhD3, Lin-Pierre Zhao, MD, PhD4, Matthieu Jestin, MD5, Megan Fraisse, MD6, Elie Azoulay, MD, PHD7, Lionel Ades, MD, PhD8, Nicolas Boissel, MD,PhD9, Emmanuel Raffoux, MD10, Sofiane Fodil, MD11
AFFILIATIONS
1 Adult Hematology Unit, Hôpital Saint-Louis, AP-HP, Paris, France
2 Adult Hematology Unit, Hôpital Saint-Louis, AP-HP, Paris, France
3 Adult Hematology Unit, Hôpital Saint-Louis, AP-HP, Paris, France
4 Senior Hematology Unit, Hôpital Saint-Louis, AP-HP, Paris, France
5 Adolescent and Young Adult Hematology Unit, Hôpital Saint-Louis, AP-HP, Paris, France
6 Medical ICU, Hôpital Saint-Louis, AP-HP, Paris, France
7 Medical ICU, Hôpital Saint-Louis, AP-HP, Paris, France
8 Senior Hematology Unit, Hôpital Saint-Louis, AP-HP, Paris, France
9 Adolescent and Young Adult Hematology Unit, Hôpital Saint-Louis, AP-HP, Paris, France
10 Adult Hematology Unit, Hôpital Saint-Louis, AP-HP, Paris, France
11 Adult Hematology Unit, Hôpital Saint-Louis, AP-HP, Paris, France
ABSTRACT
Background
Up to 25% of newly diagnosed acute myeloid leukemia (AML) patients present with hyperleukocytosis, which is associated with early mortality and severe complications. Cytoreduction remains heterogeneous and relies mostly on hydroxyurea (HU) and dexamethasone before induction therapy. Given frequent FLT3 alterations in hyperleukocytic AML and possible FLT3 ligand-driven proliferation in FLT3 wild-type (wt) disease, FLT3 inhibition may offer a broadly applicable cytoreductive approach. Since March 2023, we have used gilteritinib, a FLT3 inhibitor (FLT3i), as adjunctive salvage cytoreduction after insufficient response to standard cytoreduction.
Methods
We conducted a retrospective single-center analysis of newly diagnosed acute myeloid leukemia (AML) with hyperleukocytosis comparing gilteritinib added to standard cytoreduction with HU and dexamethasone versus standard cytoreduction alone. A 2:1 nearest-neighbor propensity-score matching was performed using age, white blood cell (WBC) count, oxygen requirement, dexamethasone, disseminated intravascular coagulation (DIC), and tumor lysis syndrome (TLS). The primary objective was a composite day-90 endpoint from hospitalization, defined as death, need for life support, or absence of complete remission (CR) or complete remission with incomplete hematologic recovery (CRi). Secondary objectives included overall survival (OS), event-free survival (EFS), CR/CRi rate, early leukocyte reduction, and early safety. Outcomes were analyzed using Kaplan-Meier estimates, log-rank tests, and Cox regression models.
Results
Among 289 patients initially screened, 16 received gilteritinib as an additional cytoreductive agent and were matched to 32 patients treated with standard cytoreduction. Matching achieved good overall balance, with a mean absolute SMD of 0.05 across key baseline severity covariates. In the matched cohort, median age was 54 [45-60] and 56 [31-65] years in the standard and FLT3i groups, respectively. Median WBC count, hemoglobin, and platelet count at diagnosis were 129 G/L [86-152], 9.5 g/dL [7.45-11.25], and 41 G/L [24-85] in the standard cohort, and 130 G/L [86-170], 9.5 g/dL [7.65-12.05], and 44 G/L [22-74] in the FLT3i cohort.
At diagnosis, DIC occurred in 14 (44%) and 6 (38%) patients in the standard and FLT3i cohorts, while TLS was present in 11 (34%) and 5 (31%) patients, respectively. Oxygen support was required at diagnosis in 14 and 7 (44%) patients. The FLT3i cohort had a higher incidence of FLT3 mutations at diagnosis (13/16, 81.2% vs 16/32, 50.0%) and ELN 2022 intermediate-risk disease (12/16, 75.0% vs 18/32, 56.2%).
All patients in the FLT3i cohort and 29 (91%) patients in standard cohort received HU at time of diagnosis, dexamethasone was administered in 30 and 15 (94%) patients in both cohorts. Combined cytoreduction led to a steeper decline in WBC count compared with HU-based cytoreduction, with a 10-fold decrease reached by day 5 and a significantly greater median fold reduction before induction (13.7-fold vs 2.3-fold, p<0.001). The addition of gilteritinib was not associated with increased incidence of DIC or TLS (p=0.76 and p=1.00, respectively), and no cases of cardiovascular toxicity or differentiation syndrome were documented during cytoreduction.
Composite day-90 events occurred in 25.0% of patients in the gilteritinib group versus 43.8% in the standard group (Fisher p=0.11; robust matched HR 0.49, 95% CI 0.21-1.17, p=0.082). Oxygen support (p=0.002) and TLS (p<0.001) were identified as the most relevant independent predictors of the composite day-90 endpoint.
One-year OS was 80.2% with gilteritinib add-on versus 68.3% with standard cytoreduction alone (log-rank p=0.18; robust matched HR 0.44, 95% CI 0.14-1.40, p=0.16). One-year EFS was 80.2% versus 49.4%, respectively (log-rank p=0.054; robust matched HR 0.32, 95% CI 0.11-0.98, p=0.046). After adjustment for age, FLT3 mutation status, and ELN 2022 risk, gilteritinib add-on remained associated with improved EFS (HR 0.23, 95% CI 0.07-0.80, p=0.020).
CR/CRi was achieved in 87.5% versus 77.4% of patients in the gilteritinib and standard groups, respectively (p=0.39).
Conclusions
The addition of gilteritinib to HU and dexamethasone was feasible, with no increase in early toxicity and fewer early complications. Combined cytoreduction resulted in rapid WBC clearance, improved EFS, and a favorable trend in OS, supporting prospective evaluation in newly diagnosed AML with hyperleukocytosis.
DISCLOSURES
Alessandra Vatteroni, MD: No relevant conflicts of interest to declare.